Shionogi agreed to acquire IntraBio, paying $2 billion upfront, extending the Japanese company’s rare-disease strategy with a marketed therapy. The Texas-based IntraBio brings Aqneursa, an approved treatment for two inherited neurological disorders, with potential to expand into additional rare indications and possibly broader disease areas. The deal represents Shionogi’s second major rare-disease move this year after it also acquired global rights to an amyotrophic lateral sclerosis drug from Tanabe Pharma. Shionogi’s approach suggests continued focus on acquiring commercial or near-commercial rare assets rather than building pipelines solely from preclinical stages. For investors and rivals, the transaction underscores how rare disease remains a highly active M&A category, particularly for therapies with established regulatory footprints and identifiable commercial pull.